From the Departments of Thoracic and Cardiovascular Surgery.
Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Anesth Analg. 2023 Apr 1;136(4):719-727. doi: 10.1213/ANE.0000000000006385. Epub 2023 Feb 8.
Pulmonary resection surgery causes severe postoperative pain and usually requires opioid-based analgesia, particularly in the early postoperative period. However, the administration of large amounts of opioids is associated with various adverse events. We hypothesized that patients who underwent pulmonary resection under an enhanced recovery after surgery (ERAS) program consumed fewer opioids than patients who received conventional treatment.
A total of 2147 patients underwent pulmonary resection surgery between August 2019 and December 2020. Two surgeons (25%) at our institution implemented the ERAS program for their patients. After screening, the patients were divided into the ERAS and conventional groups based on the treatment they received. The 2 groups were then compared after the stabilized inverse probability of treatment weighting. The primary end point was the total amount of opioid consumption from surgery to discharge. The secondary end points included daily average and highest pain intensity scores during exertion, opioid-related adverse events, and clinical outcomes, such as length of intensive care unit (ICU) stay, hospital stay, and postoperative complication grade defined by the Clavien-Dindo classification. Additionally, the number of patients discharged without opioids prescription was assessed.
Finally, 2120 patients were included in the analysis. The total amount of opioid consumption (median [interquartile range]) after surgery until discharge was lower in the ERAS group (n = 260) than that in the conventional group (n = 1860; morphine milligram equivalents, 44 [16-122] mg vs 208 [146-294] mg; median difference, -143 mg; 95% CI, -154 to -132; P < .001). The number of patients discharged without opioids prescription was higher in the ERAS group (156/260 [60%] vs 329/1860 [18%]; odds ratio, 7.0; 95% CI, 5.3-9.3; P < .001). On operation day, both average pain intensity score during exertion (3.0 ± 1.7 vs 3.5 ± 1.8; mean difference, -0.5; 95% CI, -0.8 to -0.3; P < .001) and the highest pain intensity score during exertion (5.5 ± 2.1 vs 6.4 ± 1.7; mean difference, -0.8; 95% CI, -1.0 to -0.5; P < .001) were lower in the ERAS group than in the conventional group. There were no significant differences in the length of ICU stay, hospital stay, or Clavien-Dindo classification grade.
Patients who underwent pulmonary resection under the ERAS program consumed fewer opioids than those who received conventional management while maintaining no significant differences in clinical outcomes.
肺切除术可导致严重的术后疼痛,通常需要阿片类药物镇痛,尤其是在术后早期。然而,大量使用阿片类药物会引起各种不良反应。我们假设在加速康复外科(ERAS)方案下接受肺切除术的患者比接受常规治疗的患者消耗的阿片类药物更少。
2019 年 8 月至 2020 年 12 月期间,共有 2147 名患者接受了肺切除术。我们机构的 2 名外科医生(占 25%)对他们的患者实施了 ERAS 方案。筛选后,根据患者接受的治疗将他们分为 ERAS 组和常规组。在稳定的逆概率治疗加权后,对两组进行比较。主要终点是从手术到出院期间阿片类药物的总消耗量。次要终点包括用力时的每日平均和最高疼痛强度评分、阿片类药物相关不良反应以及临床结局,如重症监护病房(ICU)入住时间、住院时间和 Clavien-Dindo 分类定义的术后并发症分级。此外,评估了无阿片类药物处方出院的患者人数。
最终,2120 名患者纳入分析。ERAS 组(n = 260)比常规组(n = 1860)从手术后到出院时的阿片类药物总消耗量(中位数[四分位距])更低(吗啡毫克当量,44[16-122]mg 比 208[146-294]mg;中位数差值,-143mg;95%CI,-154 至-132;P <.001)。ERAS 组中有更多的患者无需开具阿片类药物处方出院(156/260[60%]比 329/1860[18%];优势比,7.0;95%CI,5.3-9.3;P <.001)。手术当天,用力时的平均疼痛强度评分(3.0 ± 1.7 比 3.5 ± 1.8;平均差值,-0.5;95%CI,-0.8 至-0.3;P <.001)和用力时的最高疼痛强度评分(5.5 ± 2.1 比 6.4 ± 1.7;平均差值,-0.8;95%CI,-1.0 至-0.5;P <.001)均低于常规组。两组 ICU 入住时间、住院时间或 Clavien-Dindo 分级无显著差异。
在 ERAS 方案下接受肺切除术的患者比接受常规治疗的患者消耗的阿片类药物更少,同时保持临床结局无显著差异。